R. Yale Phyllis's most recent trade in DaVita Inc was a trade of 278 Common Stock done . Disclosure was reported to the exchange on Aug. 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2026 | 278 | 9,803 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2026 | 607 | 44,986 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 May 2026 | 5,038 | 9,525 (0%) | 0% | 0 | Common Stock | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2026 | 250 | 14,563 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2026 | 577 | 43,903 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2026 | 332 | 14,313 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2026 | 3,996 | 43,326 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 648 | 38,891 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2025 | 411 | 13,981 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2025 | 776 | 37,734 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2025 | 369 | 13,570 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 756 | 36,447 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 348 | 13,201 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 573 | 35,251 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2025 | 349 | 12,853 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 3,562 | 34,677 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb | R. Yale Phyllis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 618 | 30,796 | - | - | Deferred Share Units | |
| DaVita | Yale Phyllis R. | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Dec 2024 | 3,500 | 12,504 (0%) | 0% | 0 | Common Stock | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2024 | 312 | 16,004 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 676 | 29,847 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 333 | 15,692 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2024 | 842 | 28,812 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 363 | 15,359 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2024 | 645 | 27,595 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 366 | 14,996 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 4,314 | 26,949 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb | Yale Phyllis R. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2023 | 657 | 22,359 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2023 | 529 | 14,630 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2023 | 581 | 21,463 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 475 | 14,101 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 527 | 20,689 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 516 | 13,626 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 486 | 19,995 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 658 | 13,110 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 2,807 | 19,508 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 469 | 16,568 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2022 | 677 | 12,452 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 474 | 15,988 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 514 | 11,775 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 438 | 15,400 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2022 | 475 | 11,261 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 462 | 14,855 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 429 | 10,786 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 3,067 | 14,393 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2021 | 521 | 11,232 | - | - | Deferred Share Units | |
| DaVita | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 446 | 10,357 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 549 | 10,622 | - | - | Deferred Share Units |